Skip to main content

Table 4 MGMT promoter methylation status and progress and survival of patients. Promoter methylation was determined by HRM, MSP, and PSQ

From: MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response

Promoter status HRM MSP PSQ
Methylated MGMT promoter
 Progression-free survival
  Median duration (months) 6.0 (3.64–8.36) 4.4 (3.09–5.72) 4.6 (2.88–6.32)
  Rate at 6 months (%) 51.9 40.0 46.7
 Overall survival
  Median duration (months) 14.0 (6.50–21.50) 11.0 (8.19–13.81) 11.0 (0.27–21.74)
  Rate at 18 months (%) 48.1 40.0 46.7
Unmethylated MGMT promoter
 Progression-free survival
  Median duration (months) 4.0 (3.80–4.20) 4.2 (3.67–4.73) 4.0 (3.67–4.33)
  Rate at 6 months (%) 31.6 40.0 34.3
 Overall survival
  Median duration (months) 10.0 (5.03–14.97) 12.0 (7.36–16.64) 11.0 (7.62–14.38)
  Rate at 18 months (%) 23.7 31.1 22.9
  1. Numbers in parentheses are 95 % confidence intervals
\